<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35018685</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2796</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>291</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of internal medicine</Title>
          <ISOAbbreviation>J Intern Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Primary Sjögren's syndrome: Longitudinal real-world, observational data on health-related quality of life.</ArticleTitle>
        <Pagination>
          <StartPage>849</StartPage>
          <EndPage>855</EndPage>
          <MedlinePgn>849-855</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/joim.13451</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Primary Sjögren's syndrome (pSS) is a chronic inflammatory condition, which presents with symptoms of dryness, pain, fatigue and often symptoms of anxiety and depression. Health-related quality of life (HRQoL) is significantly reduced in pSS and the direct and indirect health costs of pSS are substantial. This study aims to determine how symptom burden, disease activity and demographics associate with HRQoL longitudinally over a median of 24-month follow-up period in pSS.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Longitudinal EuroQoL-5 dimension (EQ-5D)-3L data from the Newcastle pSS cohort (n = 377) were evaluated using a survival analysis strategy. Kaplan-Meier and Cox proportional hazards analysis were performed using baseline Newcastle Sjogren's Stratification Tool (NSST) subgroup, EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI), EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI), disease duration, age and sex as covariates including polypharmacy and comorbidity score, where data were available (n = 191).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 377 pSS participants analysed in this study, 16% experienced a decline in HRQoL to a health state comparable to or worse than death. NSST subgroup and ESSPRI score had a significant relationship with time to 'EQ-5D event', whereas baseline ESSDAI, age, disease duration and sex did not.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In pSS, symptom burden and to a great extent NSST subgroup, rather than systemic disease activity, has a significant relationship with HRQoL longitudinally. Improvements in symptom burden have the potential to produce significant impacts on long-term HRQoL in pSS.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. Journal of Internal Medicine published by John Wiley &amp; Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tarn</LastName>
            <ForeName>Jessica</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0003-0083-8543</Identifier>
            <AffiliationInfo>
              <Affiliation>Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lendrem</LastName>
            <ForeName>Dennis</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McMeekin</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Health and Life Science, Northumbria University, Newcastle upon Tyne, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lendrem</LastName>
            <ForeName>Clare</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>NIHR Newcastle In Vitro Diagnostics Co-operative, Newcastle University, Newcastle upon Tyne, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hargreaves</LastName>
            <ForeName>Ben</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Musculoskeletal Directorate, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ng</LastName>
            <ForeName>Wan-Fai</ForeName>
            <Initials>WF</Initials>
            <Identifier Source="ORCID">0000-0002-5539-388X</Identifier>
            <AffiliationInfo>
              <Affiliation>Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Musculoskeletal Directorate, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>MR/J002720/1</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>G0800629</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Intern Med</MedlineTA>
        <NlmUniqueID>8904841</NlmUniqueID>
        <ISSNLinking>0954-6820</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012859" MajorTopicYN="Y">Sjogren's Syndrome</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Sjogren's</Keyword>
        <Keyword MajorTopicYN="N">health-related quality of life</Keyword>
        <Keyword MajorTopicYN="N">longitudinal</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>49</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35018685</ArticleId>
        <ArticleId IdType="doi">10.1111/joim.13451</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Higgins AM, Harris AH. Health economic methods: cost-minimization, cost-effectiveness, cost-utility, and cost-benefit evaluations. Crit Care Clin. 2012;28(1):11-24. https://doi.org/10.1016/j.ccc.2011.10.002</Citation>
        </Reference>
        <Reference>
          <Citation>Lendrem D, Mitchell S, McMeekin P, Bowman S, Price E, Pease CT, et al. Health-related utility values of patients with primary Sjögren's syndrome and its predictors. Ann Rheum Dis. 2014;73(7):1362-8. https://doi.org/10.1136/annrheumdis-2012-202863</Citation>
        </Reference>
        <Reference>
          <Citation>Lendrem D, Mitchell S, McMeekin P, Gompels L, Hackett K, Bowman S, et al. Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome? Rheumatology. 2015;54(4):655-9. https://doi.org/10.1093/rheumatology/keu361</Citation>
        </Reference>
        <Reference>
          <Citation>Tarn JR, Howard-Tripp N, Lendrem DW, Mariette X, Saraux A, Devauchelle-Pensec V, et al. Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatology. 2019;1(2):e85-94. https://doi.org/10.1016/S2665-9913(19)30042-6</Citation>
        </Reference>
        <Reference>
          <Citation>Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554-8. https://doi.org/10.1136/ard.61.6.554</Citation>
        </Reference>
        <Reference>
          <Citation>Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al. EULAR Sjogren's Syndrome Disease Activity Index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis. 2010;69:1103-9. https://doi.org/10.1136/ard.2009.110619</Citation>
        </Reference>
        <Reference>
          <Citation>Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, et al. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis. 2011;70:968-72. https://doi.org/10.1136/ard.2010.143743</Citation>
        </Reference>
        <Reference>
          <Citation>Zigmond AS, Snaith RP. The Hospital Anxiety And Depression Scale. Acta Psychiatr Scand. 1983;67(6):361-70. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x</Citation>
        </Reference>
        <Reference>
          <Citation>Bowman SJ, Booth DA, Platts RG, UK Sjögren's Interest Group. Measurement of fatigue and discomfort in primary Sjogren's syndrome using a new questionnaire tool. Rheumatology. 2004;43(6):758-64. https://doi.org/10.1093/rheumatology/keh170</Citation>
        </Reference>
        <Reference>
          <Citation>Clinical Classifications Software Refined (CCSR). Healthcare Cost and Utilization Project (HCUP). October 2021. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/toolssoftware/ccsr/ccs_refined.jsp. Last modified: 28 Oct 2021. Accessed May 21, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Janssen B, Szende A. Population norms for the EQ-5D. In: Szende A, Janssen B, Cabases J, editors. Self-reported population health: an international perspective based on EQ-5D. Dordrecht: Springer; 2014. p. 19-30. https://doi.org/10.1007/978-94-007-7596-1_3</Citation>
        </Reference>
        <Reference>
          <Citation>Gandolfo S, De Vita S. Emerging drugs for primary Sjögren's syndrome. Expert Opin Emerg Drugs. 2019;24(2):121-32. https://doi.org/10.1080/14728214.2019.1634052</Citation>
        </Reference>
        <Reference>
          <Citation>Davies K, Dures E, Ng W-F. Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research. Nat Rev Rheumatol. 2021;17(11):651-64. https://doi.org/10.1038/s41584-021-00692-1</Citation>
        </Reference>
        <Reference>
          <Citation>Al-Janabi H, Flynn TN, Coast J. Development of a self-report measure of capability wellbeing for adults: the ICECAP-A. Qual Life Res. 2012;21(1):167-76. https://doi.org/10.1007/s11136-011-9927-2</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
